Tenax Therapeutics, Inc. (TENX)

3.8400 -0.0200 (-0.52%) At close: 04:00PM EDT

Tenax Therapeutics, Inc.

101 Glen Lennox Drive
Suite 300
Chapel Hill, NC 27517
United States
(919) 855-2100
https://www.tenaxthera.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Christopher T. Giordano	CEO, President & Director	644.77k	N/A	1975
Dr. Stuart Rich M.D.	Chief Medical Officer & Director	481.22k	N/A	1950
Mr. Lawrence R. Hoffman CPA, Esq.	Interim Chief Financial Officer	N/A	N/A	1955
Mr. Doug Randall	Executive Vice President of Commercial & Business Operations	N/A	N/A	N/A
Dr. Douglas Hay	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Corporate governance

Tenax Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.